Aha 2024 2 items

Video and podcasts

3:40

AHA 2024: KRAKEN, oral muvalaplin lowers Lp(a) by up to 85 percent (Stephen Nicholls)

Stephen J. Nicholls · November 2024

5:29

AHA 2024: ALPACAR, zerlasiran in adults with elevated Lp(a) at high ASCVD risk (Steven Nissen)

Steven E. Nissen · November 2024